ScholarIQanswers from OpenAlex & ORCID
Dariusz M. Kowalski
ResearcherPublications, citations & collaboration network
Dariusz M. Kowalski is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Dariusz M. Kowalski have?
ScholarIQindexed works
Dariusz M. Kowalski has 332 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dariusz M. Kowalski have?
ScholarIQcitation count
Dariusz M. Kowalski has 28,409 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Dariusz M. Kowalski?
ScholarIQh-index
Dariusz M. Kowalski has an h-index of 44 in OpenAlex.
What is the i10-index of Dariusz M. Kowalski?
ScholarIQi10-index
Dariusz M. Kowalski has an i10-index of 99 in OpenAlex.
What is the ORCID of Dariusz M. Kowalski?
ScholarIQorcid
The ORCID for Dariusz M. Kowalski is on the source record.
What is the OpenAlex record for Dariusz M. Kowalski?
ScholarIQopenalex
The OpenAlex for Dariusz M. Kowalski is on the source record.
What are the most-cited papers on Dariusz M. Kowalski?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok, Yi‐Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, H.Z. Turna, Gilberto de Castro, Vichien Srimuninnimit, К. К. Лактионов, Igor Bondarenko, Kaoru Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, Grigory Adamchuk, Myung‐Ju Ahn, Aurelia Alexandru, Özden Altundağ, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, António Araújo, Osvaldo Rudy Aren, Oscar Arrieta Rodriguez, Touch Ativitavas, Oscar Avendaño, Fernando Barata, Carlos H. Barrios, Carlos Beato, Per Bergström, Daniel Betticher, Л. В. Болотина, Igor Bondarenko, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andrés F. Cardona, Gilberto de Castro, Hugo R. Castro, Filiz Çay Şenler, Carlos Alexandre Sydow Cerny, Alvydas Česas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao‐Hua Chiu, Byoung Chul Cho, Saulius Cicėnas, Daniel Ciurescu, Graham Cohen, Marcos André Costa, Pongwut Danchaivijitr, Flávia De Angelis, Sérgio Jobim Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, S. A. Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo dos Santos Fernandes, Carlos Gil Ferreira, Fábio Franke, H. Freitas, Yasuhito Fujisaka, Héctor Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Göker, Tuncay Göksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Håkan Griph, Mahmut Gümüş, Jacqueline A. Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernández Hernández, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz M. Kowalski, Jerónimo Rafael Rodríguez‐Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le